Imunon, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing condensed consolidated financial statements and management discussion for the period.
Key Highlights
- Cash position: Cash and cash equivalents stood at $4,039,298 as of September 30, 2026, down from $8,781,059 as of December 31, 2025, according to the filing.
- Restricted cash added: The company reported $5,039,468 in restricted cash as of September 30, 2026, compared to zero at December 31, 2025.
- Total assets: Total assets were $12,008,678 as of September 30, 2026, versus $12,288,116 as of December 31, 2025.
- Shares outstanding: As of November 12, 2026, the registrant had 6,487,286 shares of common stock, $0.01 par value per share, outstanding.
- Smaller reporting company: Imunon identified itself as a non-accelerated filer and a smaller reporting company in the filing.
- Exchange listing: Common stock is listed on NASDAQ:IMNN on the Nasdaq Capital Market.
Imunon's Balance Sheet Shifts as Restricted Cash Emerges in Q3 2026
Imunon, Inc. (NASDAQ:IMNN), a Delaware corporation headquartered at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing presents unaudited condensed consolidated financial statements alongside management's discussion and analysis of financial condition and results of operations for the three and nine months ended September 30, 2026 and 2025.
According to the filing, cash and cash equivalents declined to $4,039,298 as of September 30, 2026, from $8,781,059 at December 31, 2025. At the same time, the company reported $5,039,468 in restricted cash under other assets as of September 30, 2026, a figure that did not appear on the December 31, 2025 balance sheet. Advances and deposits on clinical programs and other current assets were $1,798,851 at September 30, 2026, compared to $1,942,685 at year-end 2025. Total current assets were reported as $5,838,149, down from $10,723,744.
Total assets as of September 30, 2026 were $12,008,678, compared to $12,288,116 as of December 31, 2025, the filing stated. Property and equipment, net of depreciation and amortization, was $393,696 at September 30, 2026, versus $529,936 at December 31, 2025. Operating lease right-of-use assets, net, were $687,365, down from $984,436. The filing contains forward-looking statements that, according to the company's cautionary language, are "subject to inherent risks and uncertainties" and may differ materially from actual results.
What Was Disclosed
Imunon filed its Form 10-Q for Q3 2026, reporting a decrease in cash and cash equivalents, the emergence of $5,039,468 in restricted cash, and total assets of $12,008,678 as of September 30, 2026, with 6,487,286 shares outstanding as of November 12, 2026.



Please wait processing your request...